Phaseline

Companies › Xenon Pharmaceuticals

Xenon Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 8 registered trials: 7 Phase 3, 1 Phase 2; Psychiatry, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Azetukalner
hERG potassium channel blocker
Ion channelsPhase 3Major Depressive Disorder; Bipolar Disorder; Bipolar DepressionDec 2026
XEN1101
Kv7 channel opener
Ion channelsPhase 3Primary Generalized Tonic-Clonic Seizures; Focal Onset Seizures; Focal EpilepsyApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06775379AzetukalnerPhase 3Major Depressive DisorderPsychiatryDec 2026
NCT06922110AzetukalnerPhase 3Major Depressive DisorderPsychiatryJan 2027
NCT05667142XEN1101Phase 3Primary Generalized Tonic-Clonic SeizuresNeurologyApr 2027
NCT07076407AzetukalnerPhase 3Major Depressive DisorderPsychiatryMay 2027
NCT05716100XEN1101Phase 3Focal Onset SeizuresNeurologyJan 2028
NCT07172516AzetukalnerPhase 3Bipolar DisorderPsychiatryJun 2028
NCT07217860AzetukalnerPhase 3Bipolar DepressionPsychiatryJun 2029
NCT03796962XEN1101Phase 2Focal EpilepsyNeurologyOct 2030

From the company's SEC filings

Cash and short-term investments of $951m on 2026-09-30; operating cash outflow about $369m a year; runway about 31 months at that burn, to Apr 2029; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 17 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

Ion channels (2)

Companies with the same targets

Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine Industrial Farmacéutica Cantabria

Companies built like this

Newron Pharmaceuticals Lipocine Actio Biosciences Rapport Therapeutics Sichuan Jishengtang Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.